FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224252648> ?p ?o ?g. }

• W4224252648 endingPage "285" @default.
• W4224252648 startingPage "277" @default.
• W4224252648 abstract "Anaplastic lymphoma kinase (ALK) is a tyrosine kinase with genomic and expression changes in many solid tumors. ALK inhibition is the first-line therapy for lung cancers with ALK alterations, and an effective therapy in other tumor types, but has not been well-studied in prostate cancer. Here, we aim to delineate the role of ALK genomic and expression changes in primary and metastatic prostate cancer. We determined ALK expression by IHC and RNA sequencing, and genomic alterations by NGS. We assessed functional consequences of ALK overexpression and pharmacologic ALK inhibition by cell proliferation and cell viability assays. Among 372 primary prostate cancer cases, we identified one case with uniformly high ALK protein expression. Genomic analysis revealed a novel SLC45A3-ALK fusion which promoted oncogenesis in in vitro assays. We observed ALK protein expression in 5 of 52 (9%) of metastatic prostate cancer cases, of which 4 of 5 had neuroendocrine features. ALK-expressing neuroendocrine prostate cancer had a distinct transcriptional program, and earlier disease progression. An ALK-expressing neuroendocrine prostate cancer model was sensitive to pharmacologic ALK inhibition. In summary, we found that ALK overexpression is rare in primary prostate cancer, but more frequent in metastatic prostate cancers with neuroendocrine differentiation. Furthermore, ALK fusions similar to lung cancer are an occasional driver in prostate cancer. Our data suggest that ALK-directed therapies could be an option in selected patients with advanced prostate cancer. Significance: Anaplastic lymphoma kinase (ALK) is a validated drug target in cancer. Here we delineate the spectrum of ALK alterations in prostate cancer. We show that ALK overexpression is present in advanced prostate cancers, in particular in cases with features of neuroendocrine carcinoma. Furthermore, ALK expression is associated with responses to pharmacologic ALK inhibition. Our study demonstrates that ALK-directed therapies should be considered in selected prostate cancer cases." @default.
• W4224252648 created "2022-04-26" @default.
• W4224252648 creator A5006631709 @default.
• W4224252648 creator A5014047283 @default.
• W4224252648 creator A5015155186 @default.
• W4224252648 creator A5017507805 @default.
• W4224252648 creator A5030953346 @default.
• W4224252648 creator A5034997866 @default.
• W4224252648 creator A5035364268 @default.
• W4224252648 creator A5039343639 @default.
• W4224252648 creator A5040822271 @default.
• W4224252648 creator A5043364780 @default.
• W4224252648 creator A5046195526 @default.
• W4224252648 creator A5049793329 @default.
• W4224252648 creator A5061239169 @default.
• W4224252648 creator A5064298275 @default.
• W4224252648 creator A5064385855 @default.
• W4224252648 creator A5067800417 @default.
• W4224252648 creator A5067987111 @default.
• W4224252648 creator A5079338108 @default.
• W4224252648 date "2022-05-02" @default.
• W4224252648 modified "2023-10-05" @default.
• W4224252648 title "Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations" @default.
• W4224252648 cites W1496247520 @default.
• W4224252648 cites W1994847090 @default.
• W4224252648 cites W2010978319 @default.
• W4224252648 cites W2021876472 @default.
• W4224252648 cites W2024963052 @default.
• W4224252648 cites W2038586807 @default.
• W4224252648 cites W2044060805 @default.
• W4224252648 cites W2054445623 @default.
• W4224252648 cites W2060275730 @default.
• W4224252648 cites W2099530756 @default.
• W4224252648 cites W2103600998 @default.
• W4224252648 cites W2104830962 @default.
• W4224252648 cites W2104853034 @default.
• W4224252648 cites W2123394258 @default.
• W4224252648 cites W2130410032 @default.
• W4224252648 cites W2134607826 @default.
• W4224252648 cites W2153782264 @default.
• W4224252648 cites W2159707944 @default.
• W4224252648 cites W2161112598 @default.
• W4224252648 cites W2161954865 @default.
• W4224252648 cites W2169456326 @default.
• W4224252648 cites W2172208023 @default.
• W4224252648 cites W2262087934 @default.
• W4224252648 cites W2292362441 @default.
• W4224252648 cites W2298285788 @default.
• W4224252648 cites W2329625383 @default.
• W4224252648 cites W2551536164 @default.
• W4224252648 cites W2581047641 @default.
• W4224252648 cites W2581592505 @default.
• W4224252648 cites W2586772225 @default.
• W4224252648 cites W2765750906 @default.
• W4224252648 cites W2782578228 @default.
• W4224252648 cites W2783889408 @default.
• W4224252648 cites W2791357477 @default.
• W4224252648 cites W2793120694 @default.
• W4224252648 cites W2801671624 @default.
• W4224252648 cites W2841858285 @default.
• W4224252648 cites W2903619166 @default.
• W4224252648 cites W2905261143 @default.
• W4224252648 cites W2922363031 @default.
• W4224252648 cites W2944403040 @default.
• W4224252648 cites W2965156742 @default.
• W4224252648 cites W2980759299 @default.
• W4224252648 cites W2993677628 @default.
• W4224252648 cites W3004981089 @default.
• W4224252648 cites W3055559170 @default.
• W4224252648 cites W3101089668 @default.
• W4224252648 cites W3132443807 @default.
• W4224252648 cites W3169779693 @default.
• W4224252648 doi "https://doi.org/10.1158/2767-9764.crc-21-0156" @default.
• W4224252648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36337169" @default.
• W4224252648 hasPublicationYear "2022" @default.
• W4224252648 type Work @default.
• W4224252648 citedByCount "2" @default.
• W4224252648 countsByYear W42242526482023 @default.
• W4224252648 crossrefType "journal-article" @default.
• W4224252648 hasAuthorship W4224252648A5006631709 @default.
• W4224252648 hasAuthorship W4224252648A5014047283 @default.
• W4224252648 hasAuthorship W4224252648A5015155186 @default.
• W4224252648 hasAuthorship W4224252648A5017507805 @default.
• W4224252648 hasAuthorship W4224252648A5030953346 @default.
• W4224252648 hasAuthorship W4224252648A5034997866 @default.
• W4224252648 hasAuthorship W4224252648A5035364268 @default.
• W4224252648 hasAuthorship W4224252648A5039343639 @default.
• W4224252648 hasAuthorship W4224252648A5040822271 @default.
• W4224252648 hasAuthorship W4224252648A5043364780 @default.
• W4224252648 hasAuthorship W4224252648A5046195526 @default.
• W4224252648 hasAuthorship W4224252648A5049793329 @default.
• W4224252648 hasAuthorship W4224252648A5061239169 @default.
• W4224252648 hasAuthorship W4224252648A5064298275 @default.
• W4224252648 hasAuthorship W4224252648A5064385855 @default.
• W4224252648 hasAuthorship W4224252648A5067800417 @default.
• W4224252648 hasAuthorship W4224252648A5067987111 @default.
• W4224252648 hasAuthorship W4224252648A5079338108 @default.
• W4224252648 hasBestOaLocation W42242526481 @default.

• next